- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bristol-Myers Squibb Company (BMY)
Fair Value
An estimate of a Bristol-Myers Squibb's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
48.80
49.50
52 wk Range
42.52
63.33
BMY Earnings
The latest earnings per share, revenues and financial reports for Bristol-Myers Squibb (BMY).
Latest Release
Oct 30, 2025
EPS / Forecast
1.63 / 1.52
Revenue / Forecast
12.20B / 11.80B
All numbers in USD
Bristol-Myers Squibb Company Earnings Call Summary for Q3/2025
- Bristol-Myers Squibb exceeded Q3 2025 forecasts with EPS of $1.63 (7.24% above expectations) and revenue of $12.2 billion, driving a 4.3% pre-market stock increase to $43.09.
- The company raised its full-year revenue guidance to $47.5-$48 billion, bolstered by 17% year-over-year growth in its growth portfolio and continued leadership in immuno-oncology.
- Key financial metrics include $6.3 billion in cash flow from operations and $1 billion in net savings, demonstrating strong operational efficiency.
- CEO Chris Boerner emphasized strategies to minimize any earnings trough, while the company projects introducing 10 new medicines by 2030.
- Despite strong performance, BMY faces potential challenges from regulatory changes, competitive pressures, supply chain disruptions, and macroeconomic factors.
Last Updated: 30/10/2025, 14:56
Read Full TranscriptFAQ
What Is Bristol-Myers Squibb's Earnings Per Share (TTM)?
The Bristol-Myers Squibb EPS (TTM) is 2.97.
When Is The Next Bristol-Myers Squibb Earnings Date?
Bristol-Myers Squibb will release its next earnings report on 04 Feb 2026.
What Is Bristol-Myers Squibb’s Revenue Forecasts For Upcoming Quarters?
Bristol-Myers Squibb’s revenue forecast is 12.21B.
How Did Bristol-Myers Squibb React to the Company's Latest Earnings Report?
Bristol-Myers Squibb reported a +7.24%% EPS surprise and a +3.39%% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 8.15%%, reflecting the market's response to the earnings results.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.